EUROPHARMA FULL ADVISORY

2026-07-17 | Cardyn Advisor | Cardyn Decision Intelligence

BRIEF I. FINANCIAL SNAPSHOT

1. EuroPharma generated MTD gross sales of $16,153,600 and MTD net profit of $3,698,448 at a 22.9% margin through July 17, 2026, representing an 8.8% revenue increase and a 10.1% profit increase versus the prior month-to-date period. YTD gross sales stand at $166,402,341 against a prior YTD of $139,172,192, reflecting 19.6% year-over-year revenue growth, with the projected month-end gross sales of $29,456,564 confirming strong July momentum. EuroPharma is pacing $199,582 ahead of its prorated monthly goal, with projected month-end net profit of $6,744,228 against a monthly goal of $6,380,284, confirming ON TRACK status. MOIC trajectory is improving, supported by the 19.6% YoY revenue growth rate, which — if sustained — materially compresses the distance to the 8.0x EBITDA exit multiple at Month 36.

BRIEF II. GEOGRAPHIC FLASH

1. DE Germany: $2,775,175 | 18.2% | 17.2% of total | ⚠ Needs Attention — lowest-margin major market, 4.7pp below network average
2. BE Belgium: $2,483,037 | 23.1% | 15.4% of total | ▨ At Plan — 9.6pp gap to 25% exit target
3. IT Italy: $2,364,587 | 26.5% | 14.6% of total | ☑ Outperforming — margin leader +3.6pp vs network average of 22.9%
4. FR France: $2,483,509 | 19.4% | 15.4% of total | ▨ At Plan — revenue competitive, margin below network average
5. NL Netherlands: $1,716,055 | 17.9% | 10.6% of total | ⚠ Needs Attention — lowest margin in network, 5.0pp below average

BRIEF III. THREE FLAGS TODAY

1. ● **Risk — Netherlands Margin Deterioration:** The Netherlands posted MTD margin of 17.9%, the lowest of all five reported markets and 5.0pp below the network average of 22.9%, with South Holland and Gelderland regions both carrying High RiskBand designations. Dutch pharmacy economics are structurally compressed by Zilveren Kruis and CZ insurer reimbursement caps and aggressive generic substitution mandates under the Geneesmiddelenvergoedingssysteem framework — the COO should initiate a contract renegotiation with the top three Dutch pharmacy chains and evaluate SKU rationalization toward higher-margin specialty lines by August 15, 2026.
2. ▨ **Watch — Belgium Revenue Share Gap:** Belgium represents 15.4% of total MTD revenue against the 25% exit target, a 9.6pp gap that must be closed within 18 months to protect exit valuation. Standard European pharma distribution practice

suggests that accelerating Belgium requires either organic volume expansion through new pharmacy chain agreements or a bolt-on acquisition of a Wallonia or Flanders-based distributor — the CEO should present a Belgium acceleration plan to the Board no later than August 1, 2026.

3. 🟢 **Opportunity — FX Tailwind Amplifying Returns:** The EUR/USD spot rate of 1.176 is 7.6 cents above the deal model assumption of 1.10, generating a YTD revenue FX impact of $24,903,752 and a +8.2% revenue uplift versus the deal model. This tailwind is currently unhedged and represents both an opportunity and a two-sided risk — the CFO should evaluate layering EUR/USD forward contracts or vanilla put options on 50–70% of projected H2 2026 EUR-denominated revenue to lock in a portion of the above-model FX gain before any EUR softening.

BRIEF IV. THREE ACTIONS REQUIRED

1. **CFO — Execute EUR/USD hedging program covering 50–70% of H2 2026 EUR revenue exposure — Due August 1, 2026** | Est. impact: $2,490,375 protected gross profit | The EUR/USD rate at 1.176 is 6.9% above the deal model; a reversion to 1.10 would eliminate the $24,903,752 YTD FX tailwind and materially impair exit EBITDA — forward contracts or vanilla puts via BNP Paribas or ING structured desk should be executed immediately.
2. **CEO — Deliver Belgium acceleration plan (organic + M&A pathway to 25% revenue share) — Due August 1, 2026** | Est. impact: est. +9.6pp revenue share recovery | Belgium at 15.4% share is 9.6pp below the exit thesis requirement; at current trajectory the target will not be met by Month 36 without either a signed pharmacy chain expansion agreement or a bolt-on acquisition of a mid-size Belgian distributor such as a Phoenix Group sub-entity or independent Wallonia operator.
3. **COO — Initiate Netherlands margin recovery program: contract renegotiation and SKU rationalization — Due August 15, 2026** | Est. impact: est. +2–3pp margin recovery | Netherlands at 17.9% margin is the network's weakest market; South Holland and Gelderland carry High RiskBand designations, and the structural compression from Dutch insurer reimbursement frameworks requires an active response — shifting volume toward specialty and branded lines less subject to Geneesmiddelenvergoedingssysteem caps is the highest-probability margin lever.

BRIEF V. MARCH PROJECTION

1. ($16,153,600 ÷ 17 days) × 31 days = $29,456,564 projected July month-end revenue; at 22.9% margin this yields projected gross profit of $6,744,228, consistent with the evidence-provided projected month-end figures. Upside driver: Italy's 26.5% margin leadership — if Italy volume accelerates by 10%, July gross profit could approach $7,418,651, meaningfully improving the annualized EBITDA run-rate. Downside risk: Netherlands and Germany margin pressure — a 10% revenue shortfall at current blended margins would reduce July gross profit to approximately $6,069,805, compressing the monthly goal surplus and flagging a potential H2 trajectory concern for LP reporting.

BRIEF VI. HIDDEN NUMBERS

1. The three lowest-margin pharmacies in the network present a concentrated recovery challenge. Vienna HealthPoint #115 carries a High RiskBand designation with gross sales, net profit, and margin data not available in the current evidence period, making it the most opaque risk in the portfolio and requiring immediate data remediation. Berlin HealthPoint #101 posted MTD gross sales of $190,525.52 at a margin of 18.1%, a High RiskBand reflecting meaningful underperformance versus the network average, consistent with Berlin's structurally competitive pharmacy market where ABDA pricing structures and DocMorris online competition suppress distributor margins. Paris HealthPoint #013 recorded MTD gross sales of $29,589.34 at a margin of 18.0%, a High RiskBand designation on the network's lowest-volume pharmacy, suggesting either a nascent account requiring volume ramp or a candidate for consolidation into a larger Île-de-France distribution node. Collectively, these three locations represent a qualitative gross profit recovery opportunity that warrants targeted operational intervention before the next LP reporting cycle.
2. The three highest-performing pharmacies demonstrate the network's margin ceiling. Brussels HealthPoint #078 generated MTD gross sales of $339,404.77 at a 23.6% margin, a Top Performer designation anchored in the Brussels-Capital region's favorable reimbursement environment and high-density specialty pharmacy demand. Liège HealthPoint #010 posted MTD gross sales of $341,907.30 at a 23.3% margin, the network's highest-revenue Top Performer, benefiting from Wallonia's concentrated pharmacy chain structure. Kraków HealthPoint #051 delivered MTD gross sales of $238,650.97 at a 28.1% margin, the highest margin in the Top Performer cohort, demonstrating that Eastern European markets can generate premium margins when specialty product mix is optimized — a playbook directly transferable to underperforming Western European locations.

I. EXECUTIVE SUMMARY

1. EuroPharma's July 2026 performance through day 17 reflects a business operating with genuine momentum. MTD gross sales of $16,153,600 and net profit of $3,698,448 at a 22.9% margin represent an 8.8% revenue and 10.1% profit improvement versus the prior month-to-date, with the projected month-end gross sales of $29,456,564 and projected net profit of $6,744,228 both exceeding the monthly goal of $6,380,284. YTD gross sales of $166,402,341 against a prior YTD of $139,172,192 confirm 19.6% year-over-year revenue growth — a rate that, if sustained, positions EuroPharma well ahead of the trajectory required to support an 8.0x EBITDA exit at Month 36. The business is pacing $199,582 ahead of its prorated monthly goal, and the ON TRACK pacing status is corroborated by the daily average of $950,212.
2. Geographically, Italy leads the network at 26.5% margin — 3.6pp above the 22.9% network average — while Germany at 18.2% and the Netherlands at 17.9% represent the two most significant margin drags. Belgium at 15.4% revenue share remains 9.6pp below the 25% exit thesis requirement, the single most consequential structural gap in the portfolio. The OTC category is the largest revenue contributor at

$5,099,437.64 MTD, with all five product categories carrying Stable or Top Performer RiskBand designations.

3. The KPI Risk Score is 0 of 4, with revenue trend, margin trend, and concentration risk all flagged OK. The primary risk is not operational but structural: Belgium's revenue share gap and the Netherlands' margin compression, if unaddressed, will constrain exit EBITDA and compress the achievable exit multiple. MOIC trajectory is improving, driven by 19.6% YoY revenue growth and a favorable EUR/USD tailwind of $24,903,752 YTD, but the next 18 months must deliver Belgium expansion and margin normalization in the Netherlands to fully realize the 8.0x exit thesis.

II. FINANCIAL PERFORMANCE

1. **A. Revenue Analysis:** Yesterday's gross sales of $822,180 compared to same-day-last-week sales of $814,371, a variance of -$48,617 at -5.6% — a modest single-day softness that does not alter the weekly trend. WTD gross sales of $4,752,528 are running 6.9% ahead of the prior WTD of $4,445,788, a $306,740 positive variance confirming that weekly momentum is intact. MTD gross sales of $16,153,600 through 17 days imply an annualized revenue run-rate of ($16,153,600 ÷ 17) × 365 = approximately $346.8M on a monthly basis, or a full-year revenue run-rate consistent with the YTD trajectory. QTD gross sales of $16,153,600 equal the MTD figure, as July is the first month of Q3 2026. Revenue momentum is accelerating on a WTD basis despite a minor daily softness.
2. **B. Profitability Analysis:** The 22.9% MTD margin sits 2.9pp above the 20% EBITDA incentive threshold, providing meaningful headroom. MTD net profit of $3,698,448 is 10.1% ahead of the prior month-to-date profit of $3,358,217, a $340,231 absolute improvement. EuroPharma is pacing $199,582 ahead of its prorated monthly goal, with projected month-end net profit of $6,744,228 representing a $363,944 surplus above the $6,380,284 monthly goal. The annualized gross profit run-rate of $3,698,448 × 12 = approximately $44.4M signals meaningful EBITDA generation capacity, though EBITDA will reflect a fraction of this figure after operating cost allocation.

III. VARIANCE ANALYSIS

1. **A. Positive Variances:** MTD revenue is $1,312,202 ahead of the prior MTD of $14,841,398, an 8.8% positive variance driven by broad-based growth across all 8 active countries, with 8 of 8 countries showing growth per the evidence. The WTD positive variance of $306,740 confirms the trend is not front-loaded. Italy's 26.5% margin and Belgium's 23.1% margin are structurally positive contributors to blended profitability. The FX tailwind — EUR/USD at 1.176 versus the 1.10 deal model — is generating a +8.2% revenue uplift and +17.6% profit uplift versus deal model assumptions, with YTD revenue FX impact of $24,903,752.
2. **B. Negative Variances:** Germany at 18.2% and the Netherlands at 17.9% are the two markets operating below the 22.9% network average, with Germany's Bavaria, Hesse, Berlin, Hamburg, and North Rhine-Westphalia regions all carrying High RiskBand designations. France at 19.4% margin also trails the network average by

3.5pp. The operational efficiency rating flags ⚠️ Margin Pressure, indicating that blended margin improvement requires active intervention in the underperforming geographies. The CFO should quantify the annualized drag from Germany and Netherlands underperformance and present a remediation roadmap to the Board by September 1, 2026.

3. **C. FX Analysis:** The EUR/USD spot rate of 1.176 is 6.9 cents above the 1.10 deal model assumption, generating a YTD revenue FX impact of $24,903,752 and a +8.2% revenue uplift. The profit FX impact is +17.6% versus the deal model. A 10% adverse EUR/USD move from current levels (to approximately 1.058) would eliminate the above-model FX benefit and introduce below-model headwinds. The CFO should engage BNP Paribas or ING's structured products desk to execute EUR/USD forward contracts or vanilla put options on 50–70% of projected H2 2026 EUR-denominated revenue, locking in a portion of the current above-model gain before any EUR softening driven by ECB rate normalization.

IV. GEOGRAPHIC SEGMENT PERFORMANCE

1. **Germany:** Germany posted MTD sales of $2,775,175, representing 17.2% of total network revenue, at a margin of 18.2% — 4.7pp BELOW the network average of 22.9%. Germany is the largest single-country revenue contributor but the second-lowest margin market, a combination that dilutes blended profitability disproportionately. The Bavaria and Hesse regions both carry High RiskBand designations, with North Rhine-Westphalia and Hamburg also in the bottom regional cohort, suggesting systemic rather than isolated margin pressure across German sub-markets. The COO should engage the German pharmacy chain management team to evaluate Lauer-Taxe reference pricing optimization and ABDA-compliant specialty product upselling as margin recovery levers by September 1, 2026.
2. **Belgium:** Belgium generated MTD sales of $2,483,037, representing 15.4% of total revenue, at a margin of 23.1% — 0.2pp ABOVE the network average of 22.9%. Belgium's margin profile is healthy and above average, but its revenue share of 15.4% is 9.6pp BELOW the 25% exit thesis target, making it the most consequential structural gap in the portfolio. The Wallonia region is a Top Performer, with Liège HealthPoint #010 and Liège HealthPoint #044 both carrying Top Performer designations, confirming that the margin infrastructure exists — the constraint is volume, not economics. The CEO must present a Belgium volume acceleration plan — including potential bolt-on acquisition of a Flanders or Wallonia distributor — to the Board by August 1, 2026.
3. **Italy:** Italy delivered MTD sales of $2,364,587, representing 14.6% of total revenue, at a margin of 26.5% — 3.6pp ABOVE the network average of 22.9%, confirming Italy's position as the network's margin leadership benchmark. The Lombardy region carries a Top Performer designation with a 26.2% margin, consistent with Italy's favorable AIFA pricing mechanisms and the Prontuario Terapeutico Nazionale framework, which supports higher distributor margins on specialty and branded pharmaceutical lines. Italy's margin leadership is structurally supported and should be sustained through continued specialty product mix optimization. The COO should

document Italy's margin management playbook for replication in Belgium and France by September 15, 2026.

4. **France:** France posted MTD sales of $2,483,509, representing 15.4% of total revenue — tied with Belgium for second-largest country share — at a margin of 19.4%, which is 3.5pp BELOW the network average of 22.9%. The Auvergne-Rhône-Alpes region is a Top Performer, with Lyon HealthPoint #073 generating $327,966.41 in MTD sales, while the Île-de-France region carries a High RiskBand at the pharmacy level, indicating geographic dispersion in French performance. France's revenue scale is competitive but margin improvement is required to avoid diluting blended profitability at exit. The COO should prioritize SKU mix optimization in Île-de-France pharmacy accounts by October 1, 2026.
5. **Netherlands:** The Netherlands generated MTD sales of $1,716,055, representing 10.6% of total revenue — the smallest country share among the five reported markets — at a margin of 17.9%, which is 5.0pp BELOW the network average of 22.9% and the lowest margin in the network. South Holland and Gelderland both carry High RiskBand designations, and North Holland is also in the bottom regional cohort, indicating network-wide Dutch margin compression driven by Zilveren Kruis and CZ insurer reimbursement caps. The Netherlands requires the most urgent margin intervention of any market. The COO should initiate Dutch contract renegotiations and specialty product volume reallocation by August 15, 2026.
6. The geographic mix across 8 active countries, with the top 3 countries representing 49.6% of total sales, reflects a moderately diversified revenue base. However, Germany's 17.2% share combined with its 18.2% margin creates a structural drag on blended profitability that will suppress exit EBITDA unless addressed. Belgium's gap to the 25% exit target remains the single most important value creation lever, and closing it through organic growth or M&A will be the primary determinant of whether the 8.0x exit multiple is achievable at Month 36.

V. PRODUCT CATEGORY PERFORMANCE

1. OTC is the network's largest category by revenue at $5,099,437.64 MTD with a 22.9% margin and Top Performer designation, followed by Wellness at $3,273,157.86 and 22.8% margin, and Prescription at $3,216,353.53 and 22.5% margin — both Top Performer. Personal Care generated $2,943,949.01 at 23.5% margin (Stable), and Medical Devices contributed $1,620,701.46 at 22.9% margin (Stable). All five categories carry Stable or Top Performer RiskBand designations, indicating no acute category-level risk. Four product categories are showing greater than 5% YoY growth per the evidence. Generic products represent 14.8% of sales — below the European pharma distribution benchmark of 25–35% — suggesting meaningful upside from generic substitution acceleration, particularly in Germany and the Netherlands where insurer frameworks incentivize generic switching. SKU productivity stands at $781,232 per active SKU across 213 active SKUs, a strong efficiency metric that supports margin sustainability at exit.

VI. RISK ASSESSMENT

1. **Customer Concentration:** The top 5 pharmacies represent 9.0% of total revenue — well BELOW the 60% concentration threshold — indicating a highly diversified customer base with no single-account dependency risk. The highest-revenue Top Performer pharmacy is Liège HealthPoint #010 at $341,907.30 MTD and 23.3% margin, a healthy profile. This low concentration level is a positive attribute for M&A buyers, as it reduces customer attrition risk in a change-of-control scenario and supports a premium exit multiple.
2. **Geographic Concentration:** Germany at 17.2% of total revenue is BELOW the 30% single-country concentration threshold, and the top 3 countries represent 49.6% of total sales — a balanced geographic distribution. However, the underperforming regions of South Holland, Gelderland, North Holland, Bavaria, Hesse, Berlin, Hamburg, and North Rhine-Westphalia — all carrying High RiskBand designations — represent a concentration of margin risk in Germany and the Netherlands that could compress exit EBITDA if not remediated. Strategic buyers evaluating EuroPharma will scrutinize this regional margin dispersion.
3. **Gross Margin Compression:** The margin compression flag is OK at the network level, with the 22.9% MTD margin sitting 2.9pp above the 20% incentive threshold. However, multiple pharmacies carry High RiskBand designations, including Berlin HealthPoint #101, Paris HealthPoint #013, Utrecht HealthPoint #021, Rotterdam HealthPoint #110, Hamburg HealthPoint #038, Rotterdam HealthPoint #019, Amsterdam HealthPoint #016, Munich HealthPoint #029, Frankfurt HealthPoint #055, Frankfurt HealthPoint #113, Munich HealthPoint #095, Munich HealthPoint #031, Arnhem HealthPoint #050, Frankfurt HealthPoint #086, Cologne HealthPoint #043, Rotterdam HealthPoint #042, Rotterdam HealthPoint #022, Munich HealthPoint #081, and Rotterdam HealthPoint #023. The collective recovery opportunity across these locations is qualitatively significant and warrants a structured margin improvement program.
4. **FX Risk:** The EUR/USD spot rate of 1.176 is 6.9 cents above the 1.10 deal model, generating a YTD revenue FX impact of $24,903,752 and a +8.2% revenue uplift. A 10% adverse move from current levels would reduce the EUR/USD rate to approximately 1.058, eliminating the above-model tailwind and introducing below-model headwinds on both revenue and profit. The CFO should execute EUR/USD forward contracts or vanilla put options on 50–70% of H2 2026 EUR revenue exposure by August 1, 2026.
5. **Overall:** The KPI Risk Score is 0 of 4, with all three monitored risk flags — revenue trend, margin trend, and concentration risk — rated OK. For LP reporting purposes, this is a clean risk profile at the network level, though the structural Belgium gap and regional margin dispersion in Germany and the Netherlands should be disclosed as watch items in the next quarterly LP update.

VII. OPERATIONAL METRICS

1. The network operates 120 active pharmacies generating 125,891 total transactions at an average transaction value of $8,538 and 4.4 units per transaction, with a cost per unit of $883.60. The operational efficiency rating carries a ⚠️ Margin Pressure flag despite the 🌟 Exceeding (+10%) overall performance status — a combination

that signals revenue outperformance is masking unit economics pressure. Industry benchmarks for European pharmaceutical distributors suggest that average transaction values above $8,000 are consistent with a specialty-weighted product mix, which supports the thesis of shifting volume toward higher-margin branded and specialty lines in Germany and the Netherlands. At 120 active pharmacies and 213 active SKUs generating $781,232 per SKU, the network's operational infrastructure is scalable to support Belgium expansion without proportional cost increases.

VIII. VALUE CREATION PROGRESS

1. **Belgium Expansion:** Belgium currently represents 15.4% of total MTD revenue against the 25% exit target — a gap of 9.6pp. At current revenue trajectory, Belgium is At Risk of missing the 25% target by Month 36 without deliberate intervention. Closing the gap requires either a significant organic volume acceleration through new pharmacy chain agreements in Flanders and Wallonia, or a bolt-on acquisition of a Belgian distributor. The Wallonia region's Top Performer status confirms the margin infrastructure is in place; the constraint is pure volume. The CEO must treat Belgium as the single highest-priority value creation initiative for the next 18 months.
2. **Italy Gross Margin Leadership:** Italy's MTD margin of 26.5% is 3.6pp above the network average of 22.9%, confirming its position as the network's margin benchmark. The Lombardy region at 26.2% margin reinforces the structural nature of Italy's advantage, rooted in AIFA pricing mechanisms and specialty product mix. Sustaining this leadership requires active defense against generic substitution pressure and continued investment in specialty distribution capabilities in Lombardy and other Italian regions.
3. **Exit Readiness and MOIC Trajectory:** The annualized gross profit run-rate of $3,698,448 × 12 = approximately $44.4M. EBITDA, typically 4–8% of revenue for European pharma distributors, implies a range consistent with the exit thesis at the upper end of that band. MOIC trajectory is improving, supported by 19.6% YoY revenue growth and a $24,903,752 FX tailwind. The next 18 months must deliver Belgium to 25% revenue share, Netherlands margin recovery, and sustained Italy margin leadership to fully support the 8.0x exit multiple.

IX. RECOMMENDED ACTIONS

1. **CFO — Execute EUR/USD hedging program (forward contracts or vanilla puts, 50–70% of H2 2026 EUR revenue) — Due August 1, 2026** | Est. impact: $2,490,375 gross profit protected | EUR/USD at 1.176 is 6.9% above deal model; a reversion to 1.10 eliminates the $24,903,752 YTD FX tailwind — engage BNP Paribas or ING structured desk immediately.
2. **CEO — Present Belgium acceleration plan (organic + M&A pathway to 25% revenue share) to Board — Due August 1, 2026** | Est. impact: est. +9.6pp revenue share recovery required for exit thesis | Belgium at 15.4% share is the most consequential structural gap; evaluate Phoenix Group sub-entity or independent Wallonia/Flanders distributor acquisition.

3. **COO — Launch Netherlands margin recovery: Dutch insurer contract renegotiation and specialty SKU reallocation — Due August 15, 2026** | Est. impact: est. +2–3pp margin recovery | Netherlands at 17.9% is the network's weakest margin; South Holland and Gelderland High RiskBand designations require immediate intervention against Zilveren Kruis and CZ reimbursement cap structures.
4. **COO — Document Italy margin management playbook for replication in Belgium and France — Due September 15, 2026** | Est. impact: est. +1–2pp margin improvement in target markets | Italy's 26.5% margin is 3.6pp above network average; the AIFA-aligned specialty product mix strategy is directly transferable to Belgian and French pharmacy accounts.
5. **CFO — Remediate Vienna HealthPoint #115 data gap and establish complete margin reporting for all 120 pharmacies — Due July 31, 2026** | Est. impact: data not available — risk unknown | Vienna HealthPoint #115 carries a High RiskBand with no gross sales, net profit, or margin data available; an unquantified High RiskBand pharmacy is an LP reporting liability and must be resolved before the next quarterly update.

X. FORWARD OUTLOOK

1. **Base Case:** ($16,153,600 ÷ 17) × 31 = $29,456,564 projected July revenue at 22.9% margin = $6,744,228 projected gross profit. Confidence: High, consistent with evidence-provided projected month-end figures and ON TRACK pacing status.
2. **Upside (+10%):** Italy volume acceleration and Belgium pharmacy chain expansion driving revenue to approximately $32,402,220 at sustained 22.9% margin = approximately $7,418,651 gross profit — achievable if the CEO executes a new Belgian pharmacy chain agreement in July.
3. **Downside (–10%):** Netherlands and Germany margin compression deepening, combined with EUR/USD softening, reducing revenue to approximately $26,510,908 at compressed margin = approximately $6,069,805 gross profit — the primary downside trigger is an unhedged FX reversal combined with Dutch insurer reimbursement cuts.
4. **Probability-Weighted (60/20/20):** Weighted July revenue of approximately $29,456,564 (base) × 60% + $32,402,220 × 20% + $26,510,908 × 20% = approximately $29,750,000 weighted revenue. The single most important variable for August and beyond is the pace of Belgium revenue share expansion — it is both the highest-impact value creation lever and the most time-sensitive risk to the exit thesis.

XI. PHARMACY-LEVEL INTELLIGENCE — HIDDEN NUMBERS REPORT

1. **Bottom Performer Analysis:** The network's most acute pharmacy-level risk is Vienna HealthPoint #115, which carries a High RiskBand designation with gross sales, net profit, and margin data entirely absent from the current evidence — an opaque risk profile that is unacceptable at 18 months post-acquisition and must be remediated by July 31, 2026, as an unquantified High RiskBand location represents a potential LP reporting liability. Berlin HealthPoint #101 posted MTD gross sales of

$190,525.52 at a margin of 18.1%, a High RiskBand reflecting the structural compression of Berlin's pharmacy market, where DocMorris online competition and ABDA pricing structures suppress distributor margins on standard pharmaceutical lines — the operational hypothesis is that Berlin #101 is over-indexed to commodity generics and under-indexed to specialty and branded products where distributor margin is structurally protected. Paris HealthPoint #013 recorded MTD gross sales of $29,589.34 at a margin of 18.0%, a High RiskBand on the network's lowest-volume pharmacy, suggesting either a nascent account in early ramp phase or a candidate for consolidation into a larger Île-de-France hub — at this revenue scale, fixed distribution costs are likely consuming a disproportionate share of gross profit. Utrecht HealthPoint #021 generated MTD gross sales of $151,672.25 at a margin of 18.1%, a High RiskBand consistent with the broader Dutch margin compression driven by Zilveren Kruis and CZ reimbursement frameworks — the operational lever here is specialty product volume reallocation away from reimbursement-capped generics. Rotterdam HealthPoint #110 posted MTD gross sales of $101,642.27 at a margin of 18.0%, a High RiskBand that mirrors the South Holland regional pattern, where multiple Rotterdam locations are simultaneously underperforming, suggesting a systemic account management or pricing issue rather than isolated pharmacy-level factors. Collectively, these five locations represent a qualitative gross profit recovery opportunity that, if addressed through targeted specialty product mix optimization and contract renegotiation, could meaningfully improve blended network margin without requiring new pharmacy additions.

2. **Top Performer Analysis:** Brussels HealthPoint #078 generated MTD gross sales of $339,404.77 at a 23.6% margin, a Top Performer designation anchored in the Brussels-Capital region's favorable reimbursement environment and high-density specialty pharmacy demand — the transferable characteristic is the specialty product mix strategy that should be replicated across underperforming Belgian and French accounts. Liège HealthPoint #010 posted MTD gross sales of $341,907.30 at a 23.3% margin, the network's highest-revenue Top Performer, demonstrating that Wallonia's concentrated pharmacy chain structure supports both volume and margin simultaneously — a model for the Belgium expansion strategy. Kraków HealthPoint #051 delivered MTD gross sales of $238,650.97 at a 28.1% margin, the highest margin in the Top Performer cohort, confirming that Eastern European markets with lower generic substitution pressure and favorable specialty product positioning can generate premium margins that exceed even Italy's network-leading performance.
3. **Network Insight:** The 10.1pp margin spread between the network's highest-performing pharmacy (Kraków HealthPoint #051 at 28.1%) and its lowest-margin tracked locations (approximately 17.2–18.1%) signals that exit valuation positioning will depend critically on compressing this dispersion — buyers applying an 8.0x EBITDA multiple will discount for margin volatility, and narrowing the spread through the Italy playbook replication program is as important as absolute revenue growth.

1. *CARDYN Advisor™ | Cardyn — Confidential Portfolio Intelligence*
2. *Date: July 17, 2026 | Report Generated: July 17, 2026 06:00 CET*
3. *Initial Memorandum — establishing baseline metrics for ongoing portfolio monitoring.*